Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia

Decitabine is a hydrophilic drug that acts by hypomethylating DNA. Decitabine is used in Europe for the treatment of acute myeloid leukemia (AML) in patients aged ≥65 years. However, it can only be administered intravenously due to very low oral bioavailability and a large distribution volume. Oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Briot, Thomas, Roger, Emilie, Lautram, Nolwenn, Verger, Alexis, Clavreul, Anne, Lagarce, Frederic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703174/
https://www.ncbi.nlm.nih.gov/pubmed/29200853
http://dx.doi.org/10.2147/IJN.S147659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703174/
https://www.ncbi.nlm.nih.gov/pubmed/29200853
http://dx.doi.org/10.2147/IJN.S147659

Ejemplares similares